A practical reference on amino acid sequence: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-24. Anything still debated is marked as such rather than presented as settled.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
== Cost-of-living == Mercer Cost of Living Survey 2016: Bangkok ranked 74 of 209 cities (1=most expensive; 209=least expensive). The Mercer survey measures the comparative cost of more than 200 items in each city, including housing, transportation, food, clothing, household goods, and entertainment. It is designed for multinationals and governments to use in determining compensation for expatriate employees. Cost of Living Index 2015 mid-year: Thailand ranked 89 of 125 nations (1=most expensive; 125=least expensive).
Reduced dissection (cutting) of the nasal tissues—no columellar incision Decreased potential for the excessive reduction (cutting) of the nasal-tip support Reduced post-operative edema Decreased visible scarring Decreased iatrogenic (inadvertent) damage to the nose, by the surgeon Increased availability for effecting in situ procedural and technical changes Palpation that allows the surgeon to feel the interior changes effected to the nose Shorter operating room time Quicker post-surgical recovery and convalescence for the patient On the other hand, benefits of an open procedure include better visualization for surgical access, granting the surgeon greater tip precision. The open approach is therefore usually preferred for revision rhinoplasty. While the open technique provides direct visualization and greater control in complex cases, systematic reviews and meta-analyses show no significant difference in long-term functional or aesthetic outcomes (eg, NOSE and ROE scores) when compared to the closed approach. The choice of approach is primarily driven by surgeon expertise and the specific anatomical requirements of the patient.
AMP + NMN Thus, the two substrates of this enzyme are NAD+ and H2O, whereas its two products are AMP and NMN. This enzyme belongs to the family of hydrolases, specifically those acting on acid anhydrides in phosphorus-containing anhydrides. The systematic name of this enzyme class is NAD+ phosphohydrolase. Other names in common use include nicotinamide adenine dinucleotide pyrophosphatase, NADP+ pyrophosphatase, and NADH pyrophosphatase. This enzyme participates in nicotinate and nicotinamide metabolism.
=== Synthetic conjugation === ELPs can be synthetically conjugated to poly (ethylene glycol) by adding a cyclooctyne functional motif to the poly (ethylene glycol) and an azide group to the ELP. Through a cycloaddition reaction involving both of the functional groups and manipulation of the solvent pH, diblock and star polymers can be formed. Rather than forming the canonical spherical clumps above the transition temperature, this specific conjugated ELP forms a micelle with amphiphillic properties, in which the polar head groups face outward and the hydrophobic domains face inward. Such micelles may be helpful in delivering nonpolar drugs to the body.
Macroscopic methods use equations that directly model the large-scale behavior of liquids, such as their thermodynamic properties and flow behavior. Microscopic methods use equations that model the dynamics of individual molecules. Mesoscopic methods fall in between, combining elements of both continuum and particle-based models.
Sources: en.wikipedia.org
In testimony before the US Senate Foreign Relations Committee on 28 January, US Secretary of State Marco Rubio did not confirm the story when asked by Senator Jeanne Shaheen and instead only noted that Rodríguez had not been indicted, saying: "We are dealing with individuals that in our system would not be acceptable in the long term. But we are in a transition to stabilization phase. You have to work with the people currently in charge of the elements of government."
Bird said he was not trying to sabotage Clark's effort. He said he merely had told several witnesses for the state that "I don't think you should jeopardize your reputation with the way [the trial] is being handled." Clark stated he was considering legal action against Bird, whose actions, he said, were "tantamount to tampering with justice."
Since the discovery of Neanderthal remains in the 19th century, many scientists have supported the hypothesis of interbreeding between archaic and modern humans, also known as hybridization, admixture, or hybrid-origin theory. The linear view of human evolution came under scrutiny in the 1970s as different species of humans were discovered that made the simplistic concept increasingly unlikely. With the advent of advanced molecular biotechnology, whole-genome sequencing of Neanderthal and human genomes were performed that confirmed recent admixture between various human species. In 2010, evidence was published revealing unambiguous examples of interbreeding between archaic and modern humans during the Middle Paleolithic and early Upper Paleolithic. Research demonstrates that interbreeding occurred in several independent events that included Neanderthals, Denisovans, as well as several unidentified hominins. Modern day Eurasian genomes contain approximately 2% Neanderthal DNA, with traces of Denisovan heritage, while modern Melanesian people have an average of 4–6% Denisovan DNA. Denny represents the first ancient individual discovered whose parents belonged to two discrete species of humans, which will provide a unique opportunity for future comparative genetic studies. The discovery of Denny and other paleogenetic data acquired since 2010 show that human evolution should not be conceptualized as a simple linear or branched progression, but rather, as a complex interaction between related species over various periods of geographical isolation and convergence.
Polydrug use involving benzodiazepines and alcohol can result in an increased risk of blackouts, risk-taking behaviours, seizures, and overdose. Dependence and tolerance, often coupled with dosage escalation, to benzodiazepines can develop rapidly among people who misuse drugs; withdrawal syndrome may appear after as little as three weeks of continuous use. Long-term use has the potential to cause both physical and psychological dependence and severe withdrawal symptoms such as depression, anxiety (often to the point of panic attacks), and agoraphobia. Benzodiazepines and, in particular, temazepam are sometimes used intravenously, which, if done incorrectly or in an unsterile manner, can lead to medical complications including abscesses, cellulitis, thrombophlebitis, arterial puncture, deep vein thrombosis, and gangrene. Sharing syringes and needles for this purpose also brings up the possibility of transmission of hepatitis, HIV, and other diseases. Benzodiazepines are also misused intranasally, which may have additional health consequences. Once benzodiazepine dependence has been established, a clinician usually converts the patient to an equivalent dose of diazepam before beginning a gradual reduction program. A 1999–2005 Australian police survey of detainees reported preliminary findings that self-reported users of benzodiazepines were less likely than non-user detainees to work full-time and more likely to receive government benefits, use methamphetamine or heroin, and be arrested or imprisoned.
Sources: en.wikipedia.org
== Products and pipeline == Glenmark's proprietary respiratory drug RYALTRIS, a nasal spray combining an antihistamine and a corticosteroid, received U.S. FDA approval for seasonal allergic rhinitis in adults and adolescents aged 12 and above. The company launched it in the United States in 2022. By 2026 it was available in 55 countries, and in July 2026 the FDA expanded approval to children aged 6 to under 12. The company's oncology portfolio consists mainly of licensed products. It distributes Tevimbra (tislelizumab) and Brukinsa (zanubrutinib) from BeiGene, and markets envafolimab as QiNHAYO in India and selected emerging markets under a license from Jiangsu Alphamab and 3D Medicines. In 2025 Glenmark also licensed trastuzumab rezetecan from Hengrui Pharma and aumolertinib from Hansoh Pharma. In dermatology, Winlevi (clascoterone cream) received European Commission approval for acne treatment in December 2025. Glenmark holds distribution rights in 17 European Union countries. For diabetes, Glenmark launched Lirafit, a liraglutide biosimilar, in January 2024, followed by Glipiq, a semaglutide biosimilar, in March 2026. Glenmark expanded its cardiovascular brand Telma (telmisartan), launched in 2003 for hypertension, to 16 related formulations. By 2024 the brand generated annual revenue of ₹1,036 crore.
== Used carrier proteins == Keyhole limpet hemocyanin It is copper-containing respiratory protein, isolated from keyhole limpets (Megathura crenulata). Because of its evolutionary distance from mammals, high molecular weight and complex structure it is usually immunogenic in vertebrate animals. Concholepas concholepas hemocyanin (also blue carrier immunogenic orotein) It is alternative to KLH isolated from Concholepas concholepas. It has the similar immunogenic properties as KLH but better solubility and therefore better flexibility. Bovine serum albumin It is from the blood sera of cows and has similarly immunogenic properties as KLH or CCH. The cationized form of BSA (cBSA) is highly positively charged protein with significantly increased immunogenicity. This change possesses a greater number of possible conjugated antigens to the protein. Ovalbumin Also known as egg albumin, OVA is the main protein (60-75%) found in hen egg white. OVA is soluble in dimethyl sulfoxide (DMSO), which enables the conjugation of haptens that are not soluble in aqueous buffers. The immune response can be enhanced using an adjuvant injected together with the immunogen.
== Safety == HATU has been shown to induce allergic reactions. In vivo dermal sensitization studies according to OECD 429 confirmed HATU is a moderate skin sensitizer, showing a response at 1.2 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by Differential scanning calorimetry (DSC) shows HATU is potentially explosive.
Alveoli consist of two types of alveolar cell and an alveolar macrophage. The two types of cell are known as type I and type II cells (also known as pneumocytes). Types I and II make up the walls and alveolar septa. Type I cells provide 95% of the surface area of each alveoli and are flat ("squamous"), and Type II cells generally cluster in the corners of the alveoli and have a cuboidal shape. Despite this, cells occur in a roughly equal ratio of 1:1 or 6:4. Type I are squamous epithelial cells that make up the alveolar wall structure. They have extremely thin walls that enable an easy gas exchange. These type I cells also make up the alveolar septa which separate each alveolus. The septa consist of an epithelial lining and associated basement membranes. Type I cells are not able to divide, and consequently rely on differentiation from Type II cells. Type II are larger and they line the alveoli and produce and secrete epithelial lining fluid, and lung surfactant. Type II cells are able to divide and differentiate to Type I cells. The alveolar macrophages have an important role in the immune system. They remove substances which deposit in the alveoli including loose red blood cells that have been forced out from blood vessels.
The behaviour of fluids at the microscale can differ from "macrofluidic" behaviour in that factors such as surface tension, energy dissipation, and fluidic resistance start to dominate the system, as opposed to inertial effects. Microfluidics studies how these behaviours change, and how they can be worked around, or exploited for new uses. At small scales (channel size of around 100 nanometers to 500 micrometers) some unintuitive properties appear. In particular, the Reynolds number (which compares the effect of the momentum of a fluid to the effect of viscosity) can become very low. One consequence is co-flowing fluids do not necessarily mix in the traditional sense, as flow becomes laminar rather than turbulent; molecular transport between them must often be through diffusion. High specificity of chemical and physical properties (concentration, pH, temperature, shear force, etc.) can also be ensured resulting in more uniform reaction conditions and higher grade products in single and multi-step reactions.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.